DQAC RELEASES INTERPRETIVE STATEMENT REGARDING BOTULINUM TOXIN INJECTIONS AND DERMAL FILLERS
Today, the Dental Quality Assurance Commission (DQAC) released an interpretive statement regarding the use of botulinum toxin (BOTOX®) injections and dermal fillers. The interpretive statement was approved by DQAC at their July 26, 2013 meeting and filed by the Code Reviser’s office on August 20, 2013.
The statement explains that the use of BOTOX® or dermal fillers in the soft tissues throughout the face is within the scope of practice of a dentist licensed under chapter 18.32 RCW when used to treat functional or esthetic dental conditions and their direct esthetic consequences, and the treating dentist has appropriate, verifiable training and experience.
The use of botulinum toxin injections or dermal fillers outside the treatment of dental related conditions for purely cosmetic purposes is not within the scope of practice of dentists unless specialty trained as an oral and maxillofacial surgeon.
DQAC has spent the last few months crafting the interpretative statement on BOTOX® as increasing numbers dentists have asked for clarity on the issue. Dentists that currently or expect to provide BOTOX® and dermal fillers may want to review DQAC’s full interpretative statement here.
It is important to remember that interpretative statements serve to provide clarity on current laws and are not in themselves legally binding. Also remember – provisions of such services are a good time to review your insurance. Your company may offer an endorsement covering such services which should be added to the policy.
Should you have additional questions please contact Alan Wicks, WSDA General Counsel at firstname.lastname@example.org or by phone at 800-448-3368.